MedTrace Logo

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT06723080 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2025-02-11

No results posted yet for this study

Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study

Conditions

  • Moderate to Severe Atopic Dermatitis

Interventions

DRUG

VC005 low dose group

VC005 low dose group repeat administration

DRUG

VC005 high dose group

VC005 high dose group repeat administration

DRUG

VC005 Placebo group

VC005 Placebo group repeat administration

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Principal Investigators

  • qianjin Lu · Chinese Academy of Medical Sciences Hospital of Skin Disease

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2027-08-30
Completion
2027-08-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06723080 on ClinicalTrials.gov